Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis

This updated systematic review and meta-analysis pooled the results of previous clinical trials assessing the effects of pirfenidone and nintedanib on patients with pulmonary fibrosis. Scopus, the Cochrane Library, PubMed, and Web of Science were searched from the inception to April 12, 2025, to ide...

Full description

Bibliographic Details
Published in:	Annals of Thoracic Medicine
Main Authors:	Yiting Qiu, Wei Ye
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-07-01
Subjects:	6-min walk test forced vital capacity meta-analysis nintedanib pirfenidone pulmonary fibrosis
Online Access:	https://journals.lww.com/10.4103/atm.atm_132_25

Similar Items

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024-05-01)

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
by: E. Bargagli, et al.
Published: (2019-05-01)

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01)

The role of nintedanib and pirfenidone in the treatment of idiopathic pulmonary fibrosis and review of recent clinical trials of IPF therapy
by: Michał Żuber, et al.
Published: (2024-06-01)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
by: Kazutaka Takehara, et al.
Published: (2022-01-01)

Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
by: Kuo-An Chu, et al.
Published: (2020-11-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data
by: Mohammed Ayaz Khan, et al.
Published: (2023-01-01)

Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study
by: Francesca Lalla, et al.
Published: (2025-10-01)

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2024-02-01)

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
by: Vinod K. Viswanathan, et al.
Published: (2024-09-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Comparative Long-term Effects of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Real-life Study with Five-year Follow-up
by: Ayça Yanalak, et al.
Published: (2025-11-01)

Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
by: V. Cottin
Published: (2012-06-01)

Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention
by: Vito D’Agnano, et al.
Published: (2024-02-01)

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study
by: Abe M, et al.
Published: (2018-10-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al.

Efficacy of Nintedanib for Idiopathic Pulmonary Fibrosis and Its Safety for Breastfeeding and Pregnancy
by: Resyana Santoso, et al.
Published: (2025-02-01)

Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system
by: Xiangyu Sun, et al.
Published: (2024-05-01)

Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis
by: Mareike Lehmann, et al.
Published: (2018-09-01)

Real-World Experience in the Clinical Use of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Taiwan: A Post-Marketing Surveillance Study
by: Ping-Hung Kuo, et al.
Published: (2024-10-01)

Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan
by: Cheng-Yu Chang, et al.
Published: (2023-10-01)

Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
by: Hironao Hozumi, et al.
Published: (2024-07-01)

Challenges in idiopathic pulmonary fibrosis trials: the point on end-points
by: C. Albera
Published: (2011-09-01)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
by: David A. Scott, et al.
Published: (2019-08-01)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
by: Timothy M. Dempsey, et al.
Published: (2022-01-01)

Pulmonary fibrosis complicated by lung cancer: bibliometric analysis from 2004 to 2024 - research status, trends and future directions
by: Boyang Li, et al.
Published: (2025-04-01)

Treatable traits in idiopathic pulmonary fibrosis: focus on respiratory tract infections—a systematic review and a meta-analysisResearch in context
by: Zsombor Matics, et al.
Published: (2025-01-01)

Lung Fibrosis after COVID-19: Treatment Prospects
by: Evgeny Bazdyrev, et al.
Published: (2021-08-01)

Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
by: Emilie Clay, et al.
Published: (2019-01-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01)

The Management of Patients With Idiopathic Pulmonary Fibrosis
by: Paolo Spagnolo, et al.
Published: (2018-07-01)

The Role of Antifibrotic Therapy in Pulmonary Fibrosis and Lung Cancer: A Multicenter Retrospective Analysis
by: Francesco Rocco Bertuccio, et al.
Published: (2025-09-01)

Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice
by: Nana Liu, et al.
Published: (2024-01-01)

Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease
by: Marta Maggisano, et al.
Published: (2024-08-01)

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
by: Claudia Valenzuela, et al.
Published: (2020-01-01)